[1] | Weber GF, Cantor H. Differential roles of osteopontin/Eta-1 in early and late lpr disease. Clinical and Experimental Immunology 2001;126:578-583. |
[2] | Weber GF. The metastasis gene osteopontin: A candidate target for cancer therapy. Biochimica et Biophysica Acta 2001;1552:61-85. |
[3] | Weber GF, Bronson R, Ilagan J, Cantor H, Schmitz R, Mak TW. Absence of CD44 prevents sarcoma metastasis. Cancer Research 2002;62:2281-2286. |
[4] | Zhang G, He B, Weber GF. Growth factor signaling induces metastasis genes in transformed cells. A molecular connection between Akt kinase and osteopontin in breast cancer. Molecular and Cellular Biology 2003;23:6507-6519. |
[5] | He B, Weber GF. Phosphorylation of NF-kB proteins by cyclic GMP-dependent kinase: A noncanonical pathway to NF-kB activation. The European Journal of Biochemistry 2003;270:2174-2185. |
[6] | Weber GF. The absence of CD44 ameliorates Faslpr/lpr disease. Autoimmunity 2004;37:1-8. |
[7] | He B, Weber GF. Synergistic activation of the CMV promoter by NF-kB P50 and Cyclic GMP-Dependent Kinase. Biochemical and Biophysical Research Communications 2004;321:13-20. |
[8] | Craig-Mylius C, Weber GF, Coburn JL, Glickstein LG. Borrelia burgdorferi, an extracellular pathogen, circumvents osteopontin in inducing an inflammatory cytokine response. Journal of Leukocyte Biology 2005;77:710-718. |
[9] | Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF, Fagin JA. Conditional activation of the RET/PTC3 and B-RAFV600E oncoproteins in thyroid cells is associated with unique patterns of gene expression that predict distinct functional properties and a preferential role of BRAF in extracellular matrix remodeling. Cancer Research 2006;66:6521-6529. |
[10] | Weber GF. 2007. Molecular Mechanisms of Cancer. Dordrecht (Springer). |
[11] | Whalen KA, Weber GF, Benjamin TL, Schaffhausen BS. Polyomavirus middle T antigen induces the transcription of osteopontin, a gene important for migration of transformed cells. The Journal of Virology 2008;82:4946-4954. |
[12] | Syed M, Fenoglio-Preiser C, Skau KA, Weber GF. Acetylcholinesterase supports anchorage independence in colon cancer. Clinical and Experimental Metastasis 2008;25:787-798. |
[13] | Weber GF. Molecular mechanisms of metastasis. Cancer Letters 2008;270:181-190. |
[14] | Weber GF. Drug targets in cancer metastasis. In: American Association for Cancer Research 100th Annual Meeting Education Book. Philadelphia (AACR) 2009;137-140. |
[15] | Sullivan J, Blair L, Alnajar A, Aziz T, Ng CY, Chipitsyna G, Gong Q, Witkiewicz W, Weber GF, Yeo CJ, Arafat HA. Expression of a pro-metastatic splice variant of Osteopontin, OPNc, in human pancreatic ductal adenocarcinoma. Surgery 2009;146:232-240. |
[16] | Weber GF. 2010. Molecular genetics and metastasis. Encyclopedia of Life Sciences, DOI 10.1002/9780470015902.a0022447. |
[17] | Weber GF. Toward a molecular classification of cancer. Toxicology 2010;278:195-198. |
[18] | Weber GF, Lett GS, Haubein NC. Meta-analysis of Osteopontin as a clinical cancer marker. Oncology Reports 2011;25:433-441. |
[19] | Tilli TM, Franco VF, Robbs BK, Wanderley JL, Silva F, Duarte de Mello K, Viola JPB, Weber GF, Gimba ERP. Osteopontin-c splicing isoform contributes to ovarian cancer progression. Molecular Cancer Research 2011;9:280-293. |
[20] | Zhang R, Pan X, Ma S, Weber GF, Zhang G. Osteopontin enhances the expression and activity of MMP-2 via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines. PLoS ONE, 2011, in press. |
[21] | Weber GF. 2011. The cancer biomarker Osteopontin: Combination with other markers. Cancer Genomics and Proteomics. 2011, in press. |